Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
 1件: KIT 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
2 Acute myeloid leukemia 💬
 1件: KIT 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
3 Acute myeloid leukemia 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
4 Acute myeloid leukemia 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
5 Acute myeloid leukemia 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
6 Adherens junction 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
7 Adherens junction 💬
 1件: FGFR1 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
8 Adherens junction 💬
 1件: FGFR1 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
9 Adherens junction 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
10 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
11 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
12 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
13 Adrenergic signaling in cardiomyocytes 💬
 1件: ADRB2 💬 Albuterol sulfate 💬 Albuterol 16件:  2 ,  3 , 11, 12, 13, 85, 86, 89, 111, 113, 228, 231, 256, 273, 299, 340 💬
14 Adrenergic signaling in cardiomyocytes 💬
 1件: ADRB2 💬 Albuterol 💬 Albuterol 16件:  2 ,  3 , 11, 12, 13, 85, 86, 89, 111, 113, 228, 231, 256, 273, 299, 340 💬
15 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
16 Alanine, aspartate and glutamate metabolism 💬
 4件: ABAT, ALDH5A1, E4.1.1.15, E4.1.1.15 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
17 Alanine, aspartate and glutamate metabolism 💬
 4件: ABAT, ALDH5A1, E4.1.1.15, E4.1.1.15 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
18 Alanine, aspartate and glutamate metabolism 💬
 4件: ABAT, ALDH5A1, E4.1.1.15, E4.1.1.15 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
19 Aldosterone synthesis and secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
20 Aldosterone synthesis and secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
21 Aldosterone synthesis and secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
22 Alzheimer disease 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
23 Alzheimer disease 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
24 Alzheimer disease 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
25 Alzheimer disease 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
26 AMPK signaling pathway 💬
 1件: HMGCR 💬 Simvastatin 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
27 AMPK signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
28 AMPK signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
29 AMPK signaling pathway 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
30 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
31 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
32 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
33 Apelin signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
34 Apelin signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
35 Apelin signaling pathway 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
36 Arachidonic acid metabolism 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
37 Autophagy - animal 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
38 Autophagy - animal 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
39 Autophagy - animal 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
40 Autophagy - other 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
41 Autophagy - other 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
42 Autophagy - other 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
43 Axon guidance 💬
 1件: ABL1 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
44 Axon guidance 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
45 Axon guidance 💬
 2件: ABL1, SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
46 Bacterial invasion of epithelial cells 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
47 beta-Alanine metabolism 💬
 3件: ABAT, E4.1.1.15, E4.1.1.15 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
48 beta-Alanine metabolism 💬
 3件: ABAT, E4.1.1.15, E4.1.1.15 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
49 beta-Alanine metabolism 💬
 3件: ABAT, E4.1.1.15, E4.1.1.15 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
50 Bile secretion 💬
 1件: HMGCR 💬 Simvastatin 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
51 Bladder cancer 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
52 Bladder cancer 💬
 1件: FGFR3 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
53 Bladder cancer 💬
 1件: FGFR3 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
54 Bladder cancer 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
55 Bladder cancer 💬
 1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
56 Breast cancer 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
57 Breast cancer 💬
 2件: FGFR1, FLT4 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
58 Breast cancer 💬
 2件: FGFR1, FLT4 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
59 Breast cancer 💬
 1件: KIT 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
60 Breast cancer 💬
 1件: KIT 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
61 Breast cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
62 Breast cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
63 Breast cancer 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
64 Butanoate metabolism 💬
 4件: ABAT, ALDH5A1, E4.1.1.15, E4.1.1.15 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
65 Butanoate metabolism 💬
 4件: ABAT, ALDH5A1, E4.1.1.15, E4.1.1.15 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
66 Butanoate metabolism 💬
 4件: ABAT, ALDH5A1, E4.1.1.15, E4.1.1.15 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
67 C-type lectin receptor signaling pathway 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
68 C-type lectin receptor signaling pathway 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
69 Calcium signaling pathway 💬
 1件: ADRB2 💬 Albuterol sulfate 💬 Albuterol 16件:  2 ,  3 , 11, 12, 13, 85, 86, 89, 111, 113, 228, 231, 256, 273, 299, 340 💬
70 Calcium signaling pathway 💬
 1件: ADRB2 💬 Albuterol 💬 Albuterol 16件:  2 ,  3 , 11, 12, 13, 85, 86, 89, 111, 113, 228, 231, 256, 273, 299, 340 💬
71 Calcium signaling pathway 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
72 Calcium signaling pathway 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
73 Calcium signaling pathway 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
74 Calcium signaling pathway 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
75 Calcium signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
76 Calcium signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
77 Calcium signaling pathway 💬
 1件: HRH1 💬 Loratadine 💬 Loratadine 5件: 13, 19, 46, 89, 98 💬
78 Calcium signaling pathway 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
79 Calcium signaling pathway 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
80 Calcium signaling pathway 💬
 1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
81 cAMP signaling pathway 💬
 1件: ADRB2 💬 Albuterol sulfate 💬 Albuterol 16件:  2 ,  3 , 11, 12, 13, 85, 86, 89, 111, 113, 228, 231, 256, 273, 299, 340 💬
82 cAMP signaling pathway 💬
 1件: ADRB2 💬 Albuterol 💬 Albuterol 16件:  2 ,  3 , 11, 12, 13, 85, 86, 89, 111, 113, 228, 231, 256, 273, 299, 340 💬
83 cAMP signaling pathway 💬
 1件: SSTR2 💬 Octreotide 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
84 cAMP signaling pathway 💬
 1件: SSTR2 💬 Octreotide acetate 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
85 cAMP signaling pathway 💬
 1件: SSTR2 💬 Octreotide pamoate 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
86 cAMP signaling pathway 💬
 1件: SSTR2 💬 Octreotide acetate 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
87 Cell cycle 💬
 1件: ABL1 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
88 Cell cycle 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
89 Cell cycle 💬
 1件: ABL1 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
90 Cellular senescence 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
91 Cellular senescence 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
92 Cellular senescence 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
93 Central carbon metabolism in cancer 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
94 Central carbon metabolism in cancer 💬
 5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
95 Central carbon metabolism in cancer 💬
 5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
96 Central carbon metabolism in cancer 💬
 2件: KIT, PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
97 Central carbon metabolism in cancer 💬
 2件: KIT, PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
98 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
99 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
100 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
101 cGMP-PKG signaling pathway 💬
 1件: ADRB2 💬 Albuterol sulfate 💬 Albuterol 16件:  2 ,  3 , 11, 12, 13, 85, 86, 89, 111, 113, 228, 231, 256, 273, 299, 340 💬
102 cGMP-PKG signaling pathway 💬
 1件: ADRB2 💬 Albuterol 💬 Albuterol 16件:  2 ,  3 , 11, 12, 13, 85, 86, 89, 111, 113, 228, 231, 256, 273, 299, 340 💬
103 Chemical carcinogenesis - DNA adducts 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
104 Chemical carcinogenesis - reactive oxygen species 💬
 1件: ABL1 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
105 Chemical carcinogenesis - reactive oxygen species 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
106 Chemical carcinogenesis - reactive oxygen species 💬
 2件: ABL1, SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
107 Chemical carcinogenesis - reactive oxygen species 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
108 Chemical carcinogenesis - reactive oxygen species 💬
 1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
109 Chemical carcinogenesis - receptor activation 💬
 1件: ADRB2 💬 Albuterol sulfate 💬 Albuterol 16件:  2 ,  3 , 11, 12, 13, 85, 86, 89, 111, 113, 228, 231, 256, 273, 299, 340 💬
110 Chemical carcinogenesis - receptor activation 💬
 1件: ADRB2 💬 Albuterol 💬 Albuterol 16件:  2 ,  3 , 11, 12, 13, 85, 86, 89, 111, 113, 228, 231, 256, 273, 299, 340 💬
111 Chemical carcinogenesis - receptor activation 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
112 Chemical carcinogenesis - receptor activation 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
113 Chemical carcinogenesis - receptor activation 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
114 Chemical carcinogenesis - receptor activation 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
115 Chemical carcinogenesis - receptor activation 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
116 Chemical carcinogenesis - receptor activation 💬
 1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
117 Chemokine signaling pathway 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
118 Choline metabolism in cancer 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
119 Choline metabolism in cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
120 Choline metabolism in cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
121 Choline metabolism in cancer 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
122 Choline metabolism in cancer 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
123 Choline metabolism in cancer 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
124 Choline metabolism in cancer 💬
 2件: PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
125 Choline metabolism in cancer 💬
 2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
126 Chronic myeloid leukemia 💬
 1件: ABL1 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
127 Chronic myeloid leukemia 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
128 Chronic myeloid leukemia 💬
 1件: ABL1 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
129 Circadian entrainment 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
130 Circadian entrainment 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
131 Circadian entrainment 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
132 Colorectal cancer 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
133 Colorectal cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
134 Colorectal cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
135 Colorectal cancer 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
136 Coronavirus disease - COVID-19 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
137 Cortisol synthesis and secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
138 Cortisol synthesis and secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
139 Cortisol synthesis and secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
140 Cushing syndrome 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
141 Cushing syndrome 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
142 Cushing syndrome 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
143 Cushing syndrome 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
144 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
145 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
146 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
147 Efferocytosis 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
148 Endocytosis 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
149 Endocytosis 💬
 3件: FGFR2, FGFR3, PDGFRA 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
150 Endocytosis 💬
 3件: FGFR2, FGFR3, PDGFRA 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
151 Endocytosis 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
152 Endocytosis 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
153 Endocytosis 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
154 Endometrial cancer 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
155 Epithelial cell signaling in Helicobacter pylori infection 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
156 Epithelial cell signaling in Helicobacter pylori infection 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
157 ErbB signaling pathway 💬
 1件: ABL1 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
158 ErbB signaling pathway 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
159 ErbB signaling pathway 💬
 2件: ABL1, SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
160 ErbB signaling pathway 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
161 ErbB signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
162 ErbB signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
163 ErbB signaling pathway 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
164 Estrogen signaling pathway 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
165 Estrogen signaling pathway 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
166 Fluid shear stress and atherosclerosis 💬
 1件: KDR 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
167 Fluid shear stress and atherosclerosis 💬
 1件: KDR 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
168 Fluid shear stress and atherosclerosis 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
169 Fluid shear stress and atherosclerosis 💬
 1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
170 Focal adhesion 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
171 Focal adhesion 💬
 5件: FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
172 Focal adhesion 💬
 5件: FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
173 Focal adhesion 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
174 Focal adhesion 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
175 Focal adhesion 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
176 Focal adhesion 💬
 1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
177 FoxO signaling pathway 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
178 GABAergic synapse 💬
 3件: ABAT, E4.1.1.15, E4.1.1.15 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
179 GABAergic synapse 💬
 3件: ABAT, E4.1.1.15, E4.1.1.15 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
180 GABAergic synapse 💬
 3件: ABAT, E4.1.1.15, E4.1.1.15 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
181 GABAergic synapse 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
182 Gap junction 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
183 Gap junction 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
184 Gap junction 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
185 Gap junction 💬
 2件: PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
186 Gap junction 💬
 2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
187 Gap junction 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
188 Gastric acid secretion 💬
 1件: SSTR2 💬 Octreotide 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
189 Gastric acid secretion 💬
 1件: SSTR2 💬 Octreotide acetate 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
190 Gastric acid secretion 💬
 1件: SSTR2 💬 Octreotide pamoate 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
191 Gastric acid secretion 💬
 1件: SSTR2 💬 Octreotide acetate 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
192 Gastric cancer 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
193 Gastric cancer 💬
 1件: FGFR2 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
194 Gastric cancer 💬
 1件: FGFR2 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
195 Gastric cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
196 Gastric cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
197 Gastric cancer 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
198 Glioma 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
199 Glioma 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
200 Glioma 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
201 Glioma 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
202 Glioma 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
203 Glioma 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
204 Glioma 💬
 2件: PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
205 Glioma 💬
 2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
206 GnRH secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
207 GnRH secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
208 GnRH secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
209 GnRH signaling pathway 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
210 GnRH signaling pathway 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
211 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
212 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
213 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
214 Growth hormone synthesis, secretion and action 💬
 1件: SSTR2 💬 Octreotide 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
215 Growth hormone synthesis, secretion and action 💬
 1件: SSTR2 💬 Octreotide acetate 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
216 Growth hormone synthesis, secretion and action 💬
 1件: SSTR2 💬 Octreotide pamoate 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
217 Growth hormone synthesis, secretion and action 💬
 1件: SSTR2 💬 Octreotide acetate 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
218 Hematopoietic cell lineage 💬
 1件: KIT 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
219 Hematopoietic cell lineage 💬
 1件: KIT 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
220 Hepatitis B 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
221 Hepatitis C 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
222 Hepatocellular carcinoma 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
223 Hepatocellular carcinoma 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
224 Hepatocellular carcinoma 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
225 Hepatocellular carcinoma 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
226 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
227 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
228 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
229 Herpes simplex virus 1 infection 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
230 HIF-1 signaling pathway 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
231 HIF-1 signaling pathway 💬
 1件: FLT1 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
232 HIF-1 signaling pathway 💬
 1件: FLT1 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
233 HIF-1 signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
234 HIF-1 signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
235 HIF-1 signaling pathway 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
236 HIF-1 signaling pathway 💬
 1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
237 Hormone signaling 💬
 1件: ADRB2 💬 Albuterol sulfate 💬 Albuterol 16件:  2 ,  3 , 11, 12, 13, 85, 86, 89, 111, 113, 228, 231, 256, 273, 299, 340 💬
238 Hormone signaling 💬
 1件: ADRB2 💬 Albuterol 💬 Albuterol 16件:  2 ,  3 , 11, 12, 13, 85, 86, 89, 111, 113, 228, 231, 256, 273, 299, 340 💬
239 Hormone signaling 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
240 Hormone signaling 💬
 1件: SSTR2 💬 Octreotide 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
241 Hormone signaling 💬
 1件: SSTR2 💬 Octreotide acetate 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
242 Hormone signaling 💬
 1件: SSTR2 💬 Octreotide pamoate 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
243 Hormone signaling 💬
 1件: SSTR2 💬 Octreotide acetate 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
244 Human cytomegalovirus infection 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
245 Human cytomegalovirus infection 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
246 Human cytomegalovirus infection 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
247 Human cytomegalovirus infection 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
248 Human cytomegalovirus infection 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
249 Human cytomegalovirus infection 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
250 Human cytomegalovirus infection 💬
 1件: PDGFRA 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
251 Human cytomegalovirus infection 💬
 1件: PDGFRA 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
252 Human cytomegalovirus infection 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
253 Human cytomegalovirus infection 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
254 Human cytomegalovirus infection 💬
 1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
255 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
256 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
257 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
258 Human papillomavirus infection 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
259 Human papillomavirus infection 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
260 Human papillomavirus infection 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
261 Human papillomavirus infection 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
262 Human papillomavirus infection 💬
 1件: PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
263 Human papillomavirus infection 💬
 1件: PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
264 Human papillomavirus infection 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
265 Human papillomavirus infection 💬
 1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
266 Huntington disease 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
267 Huntington disease 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
268 Huntington disease 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
269 IL-17 signaling pathway 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
270 Inflammatory mediator regulation of TRP channels 💬
 1件: HRH1 💬 Loratadine 💬 Loratadine 5件: 13, 19, 46, 89, 98 💬
271 Inflammatory mediator regulation of TRP channels 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
272 Insulin resistance 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
273 Insulin resistance 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
274 Insulin resistance 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
275 Insulin signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
276 Insulin signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
277 Insulin signaling pathway 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
278 JAK-STAT signaling pathway 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
279 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
280 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
281 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
282 JAK-STAT signaling pathway 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
283 JAK-STAT signaling pathway 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
284 JAK-STAT signaling pathway 💬
 2件: PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
285 JAK-STAT signaling pathway 💬
 2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
286 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
287 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
288 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
289 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
290 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
291 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
292 Leishmaniasis 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
293 Lipid and atherosclerosis 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
294 Longevity regulating pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
295 Longevity regulating pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
296 Longevity regulating pathway 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
297 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
298 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
299 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
300 MAPK signaling pathway 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
301 MAPK signaling pathway 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
302 MAPK signaling pathway 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
303 MAPK signaling pathway 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
304 MAPK signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
305 MAPK signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
306 MAPK signaling pathway 💬
 2件: KIT, PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
307 MAPK signaling pathway 💬
 2件: KIT, PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
308 MAPK signaling pathway 💬
 1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
309 Melanogenesis 💬
 1件: KIT 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
310 Melanogenesis 💬
 1件: KIT 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
311 Melanoma 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
312 Melanoma 💬
 3件: FGFR1, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
313 Melanoma 💬
 3件: FGFR1, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
314 Melanoma 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
315 Melanoma 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
316 MicroRNAs in cancer 💬
 1件: ABL1 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
317 MicroRNAs in cancer 💬
 2件: ABL1, PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
318 MicroRNAs in cancer 💬
 2件: ABL1, PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
319 MicroRNAs in cancer 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
320 MicroRNAs in cancer 💬
 3件: FGFR3, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
321 MicroRNAs in cancer 💬
 3件: FGFR3, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
322 MicroRNAs in cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
323 MicroRNAs in cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
324 MicroRNAs in cancer 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
325 MicroRNAs in cancer 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
326 MicroRNAs in cancer 💬
 1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
327 Mitophagy - animal 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
328 mTOR signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
329 mTOR signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
330 mTOR signaling pathway 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
331 Neuroactive ligand signaling 💬
 1件: ADRB2 💬 Albuterol sulfate 💬 Albuterol 16件:  2 ,  3 , 11, 12, 13, 85, 86, 89, 111, 113, 228, 231, 256, 273, 299, 340 💬
332 Neuroactive ligand signaling 💬
 1件: ADRB2 💬 Albuterol 💬 Albuterol 16件:  2 ,  3 , 11, 12, 13, 85, 86, 89, 111, 113, 228, 231, 256, 273, 299, 340 💬
333 Neuroactive ligand signaling 💬
 1件: HRH1 💬 Loratadine 💬 Loratadine 5件: 13, 19, 46, 89, 98 💬
334 Neuroactive ligand-receptor interaction 💬
 1件: ADRB2 💬 Albuterol sulfate 💬 Albuterol 16件:  2 ,  3 , 11, 12, 13, 85, 86, 89, 111, 113, 228, 231, 256, 273, 299, 340 💬
335 Neuroactive ligand-receptor interaction 💬
 1件: ADRB2 💬 Albuterol 💬 Albuterol 16件:  2 ,  3 , 11, 12, 13, 85, 86, 89, 111, 113, 228, 231, 256, 273, 299, 340 💬
336 Neuroactive ligand-receptor interaction 💬
 1件: HRH1 💬 Loratadine 💬 Loratadine 5件: 13, 19, 46, 89, 98 💬
337 Neuroactive ligand-receptor interaction 💬
 1件: SSTR2 💬 Octreotide 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
338 Neuroactive ligand-receptor interaction 💬
 1件: SSTR2 💬 Octreotide acetate 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
339 Neuroactive ligand-receptor interaction 💬
 1件: SSTR2 💬 Octreotide pamoate 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
340 Neuroactive ligand-receptor interaction 💬
 1件: SSTR2 💬 Octreotide acetate 💬 Octreotide 8件: 67, 75, 77, 84, 85, 89, 193, 227 💬
341 Neurotrophin signaling pathway 💬
 1件: ABL1 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
342 Neurotrophin signaling pathway 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
343 Neurotrophin signaling pathway 💬
 1件: ABL1 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
344 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
345 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
346 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
347 Neutrophil extracellular trap formation 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
348 NF-kappa B signaling pathway 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
349 Non-small cell lung cancer 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
350 Ovarian steroidogenesis 💬
 1件: CYP19A 💬 Letrozole 💬 Letrozole 2件: 81, 89 💬
351 Ovarian steroidogenesis 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
352 Oxytocin signaling pathway 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
353 Oxytocin signaling pathway 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
354 Oxytocin signaling pathway 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
355 Pancreatic cancer 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
356 Pancreatic cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
357 Pancreatic cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
358 Pancreatic cancer 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
359 Pancreatic cancer 💬
 1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
360 Parathyroid hormone synthesis, secretion and action 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
361 Parathyroid hormone synthesis, secretion and action 💬
 1件: FGFR1 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
362 Parathyroid hormone synthesis, secretion and action 💬
 1件: FGFR1 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
363 Pathogenic Escherichia coli infection 💬
 1件: ABL1 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
364 Pathogenic Escherichia coli infection 💬
 1件: ABL1 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
365 Pathogenic Escherichia coli infection 💬
 2件: ABL1, SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
366 Pathways in cancer 💬
 1件: ABL1 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
367 Pathways in cancer 💬
 3件: ABL1, KIT, PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
368 Pathways in cancer 💬
 3件: ABL1, KIT, PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
369 Pathways in cancer 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
370 Pathways in cancer 💬
 6件: FGFR1, FGFR2, FGFR3, FLT4, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
371 Pathways in cancer 💬
 6件: FGFR1, FGFR2, FGFR3, FLT4, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
372 Pathways in cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
373 Pathways in cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
374 Pathways in cancer 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
375 Pathways in cancer 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
376 Pathways in cancer 💬
 1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
377 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
378 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
379 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
380 Pathways of neurodegeneration - multiple diseases 💬
 1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
381 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
382 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
383 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
384 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
385 Phospholipase D signaling pathway 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
386 Phospholipase D signaling pathway 💬
 2件: KIT, PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
387 Phospholipase D signaling pathway 💬
 2件: KIT, PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
388 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
389 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
390 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
391 Phospholipase D signaling pathway 💬
 2件: PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
392 Phospholipase D signaling pathway 💬
 2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
393 PI3K-Akt signaling pathway 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
394 PI3K-Akt signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
395 PI3K-Akt signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
396 PI3K-Akt signaling pathway 💬
 2件: KIT, PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
397 PI3K-Akt signaling pathway 💬
 2件: KIT, PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
398 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
399 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
400 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
401 PI3K-Akt signaling pathway 💬
 1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
402 Platelet activation 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
403 Prolactin signaling pathway 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
404 Propanoate metabolism 💬
 1件: ABAT 💬 Divalproex sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
405 Propanoate metabolism 💬
 1件: ABAT 💬 Valproic acid 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
406 Propanoate metabolism 💬
 1件: ABAT 💬 Valproate sodium 💬 Valproic acid 13件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 89, 90, 127, 222, 331 💬
407 Prostate cancer 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
408 Prostate cancer 💬
 4件: FGFR1, FGFR2, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
409 Prostate cancer 💬
 4件: FGFR1, FGFR2, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
410 Prostate cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
411 Prostate cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
412 Prostate cancer 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
413 Prostate cancer 💬
 1件: PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
414 Prostate cancer 💬
 1件: PDGFRA 💬 Imatinib 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
415 Proteoglycans in cancer 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
416 Proteoglycans in cancer 💬
 2件: FGFR1, KDR 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
417 Proteoglycans in cancer 💬
 2件: FGFR1, KDR 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
418 Proteoglycans in cancer 💬
 1件: MTOR 💬 Everolimus 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
419 Proteoglycans in cancer 💬
 1件: MTOR 💬 Sirolimus 💬 Sirolimus 46件:  2 ,  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 97, 98, 137, 157, 158, 192, 193, 222, 227, 256, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
420 Proteoglycans in cancer 💬
 1件: MTOR 💬 Temsirolimus 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
421 Proteoglycans in cancer 💬
 1件: SRC 💬 Saracatinib 💬 Saracatinib 3件:  6 , 89, 272 💬
422 Proteoglycans in cancer 💬
 1件: VEGFA 💬 Bevacizumab 💬 Bevacizumab 8件: 13, 34, 85, 87, 89, 227, 280, 331 💬
423 Rap1 signaling pathway 💬
 1件: EGFR 💬 Cetuximab 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
424 Rap1 signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib esylate 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
425 Rap1 signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 7件: 51, 84, 85, 89, 227, 228, 331 💬
426 Rap1 signaling pathway 💬
 2件: KIT, PDGFRA 💬 Imatinib mesylate 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬